ADGRB3

Across TCGA pan-cancer cohorts, ADGRB3 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ADGRB3 data layer compared with 29 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ADGRB3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRB3 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.

MESO, LUSC, and SARC are the cancer types where ADGRB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	II,III,IV	0.121	0.571	.004	18	view →
LUSC	OS	Median	All	0.885	0.740	.004	16	view →
SARC	DFS	Median	All	0.112	0.617	<.001	14	view →
ACC	OS	Median	All	0.268	0.802	.010	12	view →
UCEC	DFS	Median	All	0.923	0.825	.026	10	view →
SCLC	OS	Median	III,IV	0.900	0.482	.011	7	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
PRAD	OS	Median	All	0.856	0.996	<.001	6	view →
LUAD	OS	Median	All	0.212	0.370	.022	4	view →
HNSC	OS	Median	All	0.230	0.609	.016	3	view →
DLBC	OS	Median	All	0.718	0.926	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ADGRB3–MESO (OS)

Open the MESO breakdown →